touchRESPIRATORY were delighted to speak with Prof. Alyn H Morice (Hull York Medical School, University of Hull, Yorkshire, UK) to discuss the phase 2 trial, investigating BLU-5937 a selective P2x3 antagonist for the treatment of refractory chronic cough.
The abstract ‘Responders Analyses in Objective 24H Cough Frequency in Soothe, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough.‘ (Abstract number: P511) was presented at ATS 2022, 13-18 May 2022.
Questions
- Could you tell us a little about the clinical burden of refractory chronic cough (RCC) and the unmet needs in its treatment? (0:31)
- What is BLU-5937 and what is the rationale for its use in the treatment of RCC? (1:45)
- What were the aims, design and eligibility criteria of the SOOTHE study? (3:09)
- What were the findings of the responder analysis? (3:48)
- What factors predicted response to BLU-5937? (4:14)
Disclosures: Alyn H Morice discloses consulting for Bellus and serving on advisory boards for Bellus.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
